Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03994705 · OUTCOME

Disease Assessment Based on International Myeloma Working Group (IMWG) Criteria

Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma · Source last updated 2025-05-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Disease assessment is on Day 21 (or at least 14 days after first Descartes-11 infusion)

What was measured

Patience with Complete response (CR) according to the International Myeloma Working Group (IMWG).

Groups in this outcome

Dose-Escalation Level 1

Participants were administered Cyclophosphamide and Fludarabine for preconditioning Participants were administered 10 million cells of Descartes-11 via intravenous catheter

Dose Level 2

Participants were administered Cyclophosphamide and Fludarabine for preconditioning Participants were administered 32 million cells of Descartes-11 via intravenous catheter

Dose Level 3

Participants were administered Cyclophosphamide and Fludarabine for preconditioning Participants were administered 100 million cells of Descartes-11 via intravenous catheter

Dose Level 4A

Participants were administered Cyclophosphamide and Fludarabine for preconditioning Participants were administered 150 million cells of Descartes-11 via intravenous catheter

Dose Level 4B

Participants were administered Cyclophosphamide and Fludarabine for preconditioning Participants were administered 150 million cells of Descartes-11 via intravenous catheter

Dose Level 4C

Participants were not administered Cyclophosphamide and Fludarabine for preconditioning Participants were administered 100 million cells of Descartes-11 via intravenous catheter

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose-Escalation Level 13
Dose Level 24
Dose Level 33
Dose Level 4A2
Dose Level 4B4
Dose Level 4C4

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Dose-Escalation Level 10Not reportedNot reportedNot reportedNot reported
Dose Level 20Not reportedNot reportedNot reportedNot reported
Dose Level 30Not reportedNot reportedNot reportedNot reported
Dose Level 4A0Not reportedNot reportedNot reportedNot reported
Dose Level 4B0Not reportedNot reportedNot reportedNot reported
Dose Level 4C0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        0
      6. group Id
        OG005
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      4
    3. group Id
      OG002
      value
      3
    4. group Id
      OG003
      value
      2
    5. group Id
      OG004
      value
      4
    6. group Id
      OG005
      value
      4
    units
    Participants
description
Patience with Complete response (CR) according to the International Myeloma Working Group (IMWG).
groups
  1. description
    Participants were administered Cyclophosphamide and Fludarabine for preconditioning Participants were administered 10 million cells of Descartes-11 via intravenous catheter
    id
    OG000
    title
    Dose-Escalation Level 1
  2. description
    Participants were administered Cyclophosphamide and Fludarabine for preconditioning Participants were administered 32 million cells of Descartes-11 via intravenous catheter
    id
    OG001
    title
    Dose Level 2
  3. description
    Participants were administered Cyclophosphamide and Fludarabine for preconditioning Participants were administered 100 million cells of Descartes-11 via intravenous catheter
    id
    OG002
    title
    Dose Level 3
  4. description
    Participants were administered Cyclophosphamide and Fludarabine for preconditioning Participants were administered 150 million cells of Descartes-11 via intravenous catheter
    id
    OG003
    title
    Dose Level 4A
  5. description
    Participants were administered Cyclophosphamide and Fludarabine for preconditioning Participants were administered 150 million cells of Descartes-11 via intravenous catheter
    id
    OG004
    title
    Dose Level 4B
  6. description
    Participants were not administered Cyclophosphamide and Fludarabine for preconditioning Participants were administered 100 million cells of Descartes-11 via intravenous catheter
    id
    OG005
    title
    Dose Level 4C
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Disease assessment is on Day 21 (or at least 14 days after first Descartes-11 infusion)
title
Disease Assessment Based on International Myeloma Working Group (IMWG) Criteria
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice